TABLE 3.

Therapeutic effect of T-3811ME and reference drugs on experimental systemic S. aureus infection in mice

Drug route and strain	Inoculum (107 CFU/mouse)	Drug	MIC (μg/ml)	ED50 (mg/mouse)	95% Confidence limit
Oral
CR-3 (GrlA mutant)	5.2	T-3811ME	0.063	0.0189a	0.0138–0.0261a
		Ciprofloxacin	2	1.33	0.899–2.87
		Levofloxacin	0.5	0.573	0.288–3.39
		Trovafloxacin	0.125	0.0805	0.0519–0.129
CRCP-9 (GrlA GyrA mutant)	2.0	T-3811ME	0.5	0.622a	0.447–0.883a
		Ciprofloxacin	8	>4
		Levofloxacin	4	>4
		Trovafloxacin	1	0.734	0.460–1.40
Subcutaneous
CR-3 (GrlA mutant)	5.2	T-3811ME	0.063	0.00493a	0.00347–0.00740a
		Ciprofloxacin	2	0.427	0.209–4.55
		Levofloxacin	0.5	0.154	0.116–0.244
CRCP-9 (GrlA GyrA mutant)	2.0	T-3811ME	0.5	0.289a	0.204–0.417a
		Ciprofloxacin	8	>4
		Levofloxacin	4	1.96	1.47–2.60

^aEquivalent to that of T-3811.